ArticleClinical rheumatology2022

Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.

Takeshi Suga et al.PubMed ↗Publisher ↗

No numbers read from the abstract.